KOBE Biomedical Innovation Cluster newsletter vol.12
- June 2021 -
vol.12 June 2021
Hello, It is still in the rainy season here in Japan, but one of the joys during this season is to see the hydrangea in bloom.
In fact, hydrangea is Kobe City's official city flower since 1970. They grow wild in a wide range of areas in Mount Rokko in Kobe, and delights us with mixture of delicate light purple and blue colors, simply catches our eyes.
If you missed our past issues, please visit E-newsletter page.
FBRI Editorial Team
This is a new series to introduce some of the most notable people who are creating, developing, and commercializing the world's most advanced medical technologies in KOBE Biomedical Innovation Cluster.
【Featured Innovator of this month】
Doctor of Medicine
Foundation for Biomedical Research and Innovation at Kobe
Research & Development Center for Cell Therapy
HACARUS Brings Sparse Modeling to Drug Discovery with Mitsubishi Tanabe Pharma
HACARUS, the provider of big insights from small data, today announced the strong results of joint research with Mitsubishi Tanabe Pharma Corporation related to the screening process, focused on first-in-class drug discovery.
Dr. Akihiko Taguchi of FBRI's research was published in the electronic version of the American scientific journal "Stem Cells"
Akihiko Taguchi et al., Department of Regenerative Medicine Research, Institute of Biomedical Research and Innovation, FBRI, have elucidated the mechanism of cerebral neuronal function regenerative and hyperinflammation control by stem cell therapy using mesenchymal stem cells.
Prof. Minako Hoshi of FBRI's research on Alzheimer's disease was published in the British Journal of Pharmacology (BJP)
Dr. Hoshi, Professor of the Department for Brain and Neurodegenerative Disease Research, FBRI and colleagues have prove that a unique toxic structure termed amyl spheroid inhibits the action of the neuron-specific sodium pump, which is essential for neuronal activity, and causes neuronal death, leading to Alzheimer's disease.
Meiji Seika Pharma Co., Ltd. and the FBRI successfully created an antibody drug candidate for the treatment of autoimmune disease through collaborative research
Meiji Seika Pharma Co., Ltd. and the FBRI were aiming to develop a revolutionary pharmaceutical as the first collaborative research program of the Kobe Biomedical Innovation Cluster. From April 2016, they performed collaborative research for five years to discover drugs for autoimmune diseases and cancer in the first "Drug Discovery Innovation Program" administered and managed by the foundation.
FBRI is a proud partner of German Entrepreneurship Asia!
Since last year, the Foundation for Biomedical Research and Innovation at Kobe (FBRI) has partnered with German Entrepreneurship Asia to support the Japan Market Discovery (Next Step) program. FBRI and German Entrepreneurship Asia continue their collaboration to support high potential German startups in exploring Japan's MedTech market and medical regulations through seminars and mentoring sessions.